Vacc-4x: Preliminary Phase II data

Preliminary data from a single-blind, placebo-controlled, Norwegian Phase II trial in 24 HIV-infected patients who were stable on antiretroviral therapy (ART) showed that intranasal Vacc-4x plus Endocine adjuvant produced increased vaccine-related immune responses as measured by a DTH skin test during the 8-week trial, while Endocine alone did not. Intranasal Vacc-4x plus Endocine was well tolerated with mild sensations in the nose on the day of administration reported. ...